Fluxion wins NIH grant for development of microbial screening platform

The Phase I NIH grant will enable the company to further develop its innovative microfluidic platform for cellular research and drug discovery. The newly awarded grant is focused on the development of a higher throughput microfluidic system for anti-microbial drug discovery and development.

The principal aims of the grant include novel detection methods for anti-microbial effectiveness and systems for conducting multi-point dose response curves.

Carolyn Conant, project leader for the grant, said: “The ability to rapidly screen and characterize anti-microbial compounds will be a powerful tool for developing the next generation of drug therapies.”